8-K current report · filed Sep 3, 2026

LB PHARMACEUTICALS INC (LBRX) 8-K Current Report: September 3, 2026

Item EX-99.1Item 7.01Item 5.02LBRX overview

Short answer

LB PHARMACEUTICALS INC (LBRX) filed an 8-K current report with the SEC on September 3, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure), Item 5.02 (Departure/Election of Directors or Officers). Joseph M. Miller appointed CFO effective September 2, 2026, bringing public biotech and commercial-stage finance experience.

LB PHARMACEUTICALS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Joseph M. Miller appointed CFO effective September 2, 2026, bringing public biotech and commercial-stage finance experience
  • Initial base salary $530,000, with target annual bonus equal to 40% of salary
  • Inducement option for 200,000 shares, vesting over four years, creating potential shareholder dilution
  • Change-of-control severance includes one year’s salary, 150% of target bonus, 12 months’ COBRA and accelerated equity vesting
  • Non-change-of-control severance includes nine months’ salary continuation and up to nine months’ COBRA reimbursement

Item 7.01 · Regulation FD Disclosure

  • CFO appointment announced for Mr. Miller, making him responsible for financial reporting, capital planning, and investor communications
  • Leadership transition may affect financial strategy and execution, depending on Mr. Miller’s background
  • Exhibit 99.1 contains the appointment announcement and potentially relevant biographical or transition details

Item EX-99.1 · Exhibit EX-99.1

  • Joseph Miller appointed CFO, adding commercialization and public-biotech finance experience ahead of pivotal NOVA-2 results
  • Miller previously supported Aurinia Pharmaceuticals through LUPKYNIS launch and commercial infrastructure expansion
  • Appointment signals preparation for potential LB-102 commercialization in schizophrenia if approved
  • Key investor risks remain clinical failure, regulatory rejection, funding needs and dependence on LB-102

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other LB PHARMACEUTICALS INC 8-K filings

Get the next LBRX 8-K as it lands

Follow LBRX for push alerts, or ask the research agent what this filing means.